Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer Journal Article

  


Authors: Rosenbluth, B. D.; Serrano, V.; Happersett, L.; Shaha, A. R.; Tuttle, R. M.; Narayana, A.; Wolden, S. L.; Rosenzweig, K. E.; Chong, L. M.; Lee, N. Y.
Article Title: Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer
Abstract: Purpose: Intensity-modulated radiation therapy (IMRT) enables highly conformal treatment for thyroid cancer (TC). In this study, we review outcomes/toxicity in a series of TC patients treated with IMRT. Methods and Materials: Between July 2001 and January 2004, 20 nonanaplastic TC patients underwent IMRT. Mean age was 55. There were 3 T2 and 17 T4 patients. Sixteen patients had N1 disease. Seven patients had metastases before RT. Fifteen underwent surgery before RT. Radioactive iodine (RAI) and chemotherapy were used in 70% and 40%, respectively. Median total RT dose was 63 Gy. Results: With two local failures, 2-year local progression-free rate was 85%. There were six deaths, with a 2-year overall survival rate of 60%. For patients with M0 disease, the 2-year distant metastases-free rate was 46%. The worst acute mucositis and pharyngitis was Grade 3 (n = 7 and 3, respectively). Two patients had Grade 3 acute skin toxicity and 2 had Grade 3 acute laryngeal toxicity. No significant radiation-related late effects were reported. Conclusions: IMRT for TC is feasible and effective in appropriately selected cases. Acute toxicity is manageable with proactive clinical care. Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are needed to confirm these preliminary findings and to clarify late toxicities. © 2005 Elsevier Inc.
Keywords: adolescent; adult; cancer chemotherapy; cancer survival; clinical article; controlled study; treatment outcome; aged; middle aged; cancer surgery; survival rate; treatment failure; intensity modulated radiation therapy; cisplatin; doxorubicin; cancer growth; skin toxicity; treatment planning; radiation dose; chemotherapy; cancer staging; cancer grading; treatment indication; metastasis; etoposide; mucosa inflammation; radiotherapy dosage; radiotherapy; carcinoma, papillary; radiation injury; oncology; cancer mortality; pneumonia; cause of death; dysphagia; disease severity; feasibility study; radioactive iodine; tumors; radiotherapy, intensity-modulated; taste disorder; xerostomia; surgery; thyroid cancer; thyroid neoplasms; toxicity; acute toxicity; anaplastic carcinoma; carcinoma, medullary; iodine; hoarseness; pharyngitis; intensity-modulated; intensity-modulated radiation therapy (imrt); larynx injury; laryngeal toxicity; overall survival (os) rates; thyroid cancer (tc); lhermitte mcalpine syndrome
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 63
Issue: 5
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2005-12-01
Start Page: 1419
End Page: 1426
Language: English
DOI: 10.1016/j.ijrobp.2005.05.043
PUBMED: 16154712
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-27744562123&partnerID=40&md5=5af01c49d60141c1c604a7b2ff7b7ebf
Notes: --- - "Cited By (since 1996): 26" - "Export Date: 24 October 2012" - "CODEN: IOBPD" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Benjamin D Rosenbluth
    5 Rosenbluth
  2. Ashwatha Narayana
    33 Narayana
  3. Ashok R Shaha
    697 Shaha
  4. Suzanne L Wolden
    560 Wolden
  5. Robert M Tuttle
    481 Tuttle
  6. Lanceford Chong
    12 Chong
  7. Laura Happersett
    89 Happersett
  8. Nancy Y. Lee
    871 Lee
  9. Kenneth E Rosenzweig
    165 Rosenzweig
  10. Victoria Serrano
    9 Serrano
Related MSK Work